Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders
Objective
PRIMARY: To determine the effect of maintenance obinutuzumab on duration of response (PR or CR) in patients with CD20+B-cell PCNSL who attain PR or CR to first-line treatment with high-dose methotrexate-based chemotherapy.
SECONDARY: To evaluate overall survival after PR or CR (OS-PRCR). To evaluate neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity. Progression-free survival (PFS) and overall survival (OS) will be calculated.
